The Obstacle of the Nonresponder 

‘As we come to appreciate the heterogeneity of cancer, which differs not only among patients with the same type and stage but also in the same patient as the tumor progresses, the value of sensitive biomarkers has increased.’ —Scott T. Tagawa, MD‘We are not alone in the effort to bring forward immunotherapy in difficult malignancies frequently diagnosed at late stages, such as lung cancer, but we are certainly among the leaders in this field.’ —Naiyer Rizvi,